EU regulator recommends positive opinion of AstraZeneca’s experimental breast cancer drug

ReutersFri, May 22, 2026 at 10:44 AM UTC

0

FILE PHOTO: The logo for AstraZeneca is seen outside its North America headquarters in Wilmington, Delaware, U.S., March 22, 2021. REUTERS/Rachel Wisniewski/File Photo

May 22 (Reuters) - ‌A ‌European Medicines ​Agency committee said ‌on ⁠Friday it ⁠has ​adopted ​a ​positive ‌opinion of AstraZeneca’s experimental ‌breast ​cancer ​drug, ​camizestrant.

Advertisement

(Reporting ‌by Ankita ​Bora ​in ​Bengaluru; ‌Editing by ​Tasim ​Zahid)

Original Article on Source

Source: “AOL Money”